The FDA granted clearance to Oculus, Inc. for the use of their stable Microcyn superoxidized water wound care system:
Hoji Alimi, founder and president of Oculus Innovative Sciences, today announced that the company has received its first 510K clearance from the U.S. Food and Drug Administration to market Dermacyn(TM) Wound Care, formulated with Microcyn(TM) Technology, as a medical device for moistening, lubricating and debriding of acute and traumatic wounds and burns.
Microcyn(TM) Technology is a super-oxidized, pH-neutral solution that is ready for use with no dilution or mixing, and requires no special handling or disposal. It is manufactured using a sophisticated, multi-chamber electrolysis process in which ionic species are selectively produced and isolated. This process allows for the production of a pH-neutral solution while minimizing the level of chlorine in the final product.